EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G)

Nozomu Machida iD, Takehiro Okumura iD, Narikazu Boku iD, Junji Kishimoto iD, Tomohiro Nishina iD, Koichi Suyama iD, Yasuhisa Ohde iD, Katsunori Shinozaki iD, Hideo Baba iD, Shinya Tokunaga, Hisato Kawakami iD, Takashi Tsuda iD und 7 weitere

Cancer · 2025

DOI: 10.1002/cncr.35807 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von Nozomu Machida und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: West Japan Oncology Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical significance of adjuvant chemotherapy after lung metastasectomy for colorectal cancer remains unknown. This phase 2 study evaluated adjuvant chemotherapy with modified 5‐fluorouracil/leucovorin and oxaliplatin (mFOLFOX6) after lung metastasectomy.

Methods

Eligibility criteria included colorectal adenocarcinoma, first curative resection of ≤4 lung metastases, and no prior chemotherapy. Treatment consisted of 12 cycles of mFOLFOX6. The primary endpoint was the 5‐year overall survival (OS) rate, with the expectation of 50% (threshold, 35%) and a planned sample size of 100 (90% power; alpha error, 5%).

Results

Fifty‐two patients were enrolled between July 2011 and July 2014; patient enrollment was closed prematurely because of slow accrual. Excluding four ineligible patients, the characteristics of the 48 patients in the efficacy analysis set were a median age of 62 years (range, 43–75 years), Eastern Cooperative Oncology Group performance status of 0 in 45 patients, prior resection of extrathoracic metastasis in four patients, and postoperative carcinoembryonic antigen within normal range in 43 patients; the status of lung metastasis was single in 34 patients, unilateral in 40 patients, and metachronous in 41 patients; and a disease‐free interval between primary tumor resection and diagnosis of lung metastasis of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsAdenocarcinomaHumansLeucovorinMiddle AgedMaleFemaleAgedFluorouracilAdultOrganoplatinum CompoundsChemotherapy, AdjuvantOxaliplatinMetastasectomy

Stichwörter der Autor:innen

adjuvant chemotherapycolorectal cancerlung metastasectomymodified 5‐fluorouracil/leucovorin and oxaliplatin (mFOLFOX6)oligometastasis

Substanzen

LeucovorinFluorouracilOrganoplatinum CompoundsOxaliplatin

Autor:innen und Institutionen

  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
  • Department of Surgery, University Hospital Mizonokuchi, Teikyo University School of Medicine, Kawasaki City, Kanagawa, Japan.
  • Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan.
  • Center for Clinical and Translational Research, Kyushu University Hospital, Higashi-ku, Fukuoka, Japan.
  • Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center, Matsuyama City, Ehime, Japan.
  • Department of Medical Oncology, Toranomon Hospital, Minato-ku, Tokyo, Japan.

ORCID-Profile: Nozomu Machida, Takehiro Okumura, Narikazu Boku, Junji Kishimoto, Tomohiro Nishina, Koichi Suyama, Yasuhisa Ohde, Katsunori Shinozaki, Hideo Baba, Hisato Kawakami, Takashi Tsuda, Masahito Kotaka, Hiroyuki Okuda, Hisateru Yasui, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro, Ichinosuke Hyodo

Förderung

  • West Japan Oncology Group

Zitieren

APA

Machida, N., Okumura, T., Boku, N., Kishimoto, J., Nishina, T., Suyama, K., Ohde, Y., Shinozaki, K., Baba, H., Tokunaga, S., Kawakami, H., Tsuda, T., Kotaka, M., Okuda, H., Yasui, H., Yamazaki, K., Hironaka, S., Muro, K., & Hyodo, I. (2025). A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G). Cancer. https://doi.org/10.1002/cncr.35807

Vancouver

Machida N, Okumura T, Boku N, Kishimoto J, Nishina T, Suyama K, et al. A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G). Cancer. 2025. doi:10.1002/cncr.35807

BibTeX
@article{Machida2025,
  author = {Machida, Nozomu and Okumura, Takehiro and Boku, Narikazu and Kishimoto, Junji and Nishina, Tomohiro and Suyama, Koichi and Ohde, Yasuhisa and Shinozaki, Katsunori and Baba, Hideo and Tokunaga, Shinya and Kawakami, Hisato and Tsuda, Takashi and Kotaka, Masahito and Okuda, Hiroyuki and Yasui, Hisateru and Yamazaki, Kentaro and Hironaka, Shuichi and Muro, Kei and Hyodo, Ichinosuke},
  title = {A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G)},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35807}
}
Kostenlos starten →